Devra J. Olson

Abstract 5581: Enfortumab vedotin, an anti-Nectin-4 ADC demonstrates bystander cell killing and immunogenic cell death anti-tumor activity mechanisms of action in urothelial cancers

Bernard A. Liu, Devra J. Olson, Katie Snead et al. · Cancer Research · 2020 · 30 citations

Medicine, Oncology, Pharmacology +16

SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models

Rebecca Mazahreh, Marsha L. Mason, John J. Gosink et al. · Molecular Cancer Therapeutics · 2023 · 25 citations · Full text

Medicine, Oncology, Pharmacology +17

HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer

Devra J. Olson, Janelle Taylor, Kelsi Willis et al. · Cancer Research Communications · 2023 · 24 citations · Full text

Medicine, Oncology, Pharmacology +17

SGN-CD48A: a Novel Humanized Anti-CD48 Antibody-Drug Conjugate for the Treatment of Multiple Myeloma

Tim Lewis, Devra J. Olson, Kristine A. Gordon et al. · Blood · 2016 · 22 citations

Pharmacy, Medicinal Chemistry, Oncology +13

Abstract 1195: SGN-CD352A: A novel humanized anti-CD352 antibody-drug conjugate for the treatment of multiple myeloma

Tim Lewis, Devra J. Olson, Kristine A. Gordon et al. · Cancer Research · 2016 · 18 citations

Medicine, Immunology, Oncology +17